Curtiss-Wright earnings up next: Defense surge meets valuation test

Curtiss-Wright is expected to report Q1 EPS of $3.28 on revenue of $864.31 million, up 16.3% and 7.3% year over year, respectively, though both are down sequentially from Q4's $3.79 EPS and $946.98 million revenue. Investors are focused on defense spending tailwinds, a $400 million-plus C-17 mission computer contract, and whether record backlog can convert into faster revenue growth. The stock has more than doubled over the past year and trades near its 52-week high, but analysts see the shares as fully valued with a consensus target of $727.86 versus a current price of $728.95.

Analysis

CW is in the classic “good business, bad entry” zone: near-term fundamentals likely remain constructive, but the equity has already capitalized a lot of that strength. The more important issue is that a backlog-heavy defense/nuclear supplier can look deceptively insulated while still facing multiple compression if investors conclude the order book is already fully reflected in guidance. In that setup, even an in-line quarter can become a sell-the-news event because the market is paying for flawless execution, not just durable growth.

Second-order benefit accrues less to CW itself than to the broader defense supply chain if management sounds confident on backlog conversion and margin durability. Suppliers with higher operating leverage and lower valuation exposure could outperform if the sector tone stays strong, while names with similar end markets but weaker execution records may lag as capital rotates toward “quality at a reasonable price.” The biggest tell will be whether CW signals any acceleration in program conversion; if not, the market may start pricing backlog as a slow-release asset rather than an earnings catalyst.

The contrarian risk is that the market is treating defense and nuclear exposure as a one-way fiscal-policy trade, when the real driver is margin progression. If operating leverage stalls or mix shifts toward lower-margin work, the premium multiple can de-rate quickly over days, not months. Conversely, a clean beat paired with raised margin guidance could extend the stock’s run, but upside likely requires more than incremental EPS; it needs evidence that the next 12–18 months of growth are both faster and more durable than consensus assumes.

Key Decisions for Investors

• Post-earnings: sell a 1-2 month at-the-money call spread on CW if results are merely in-line; the stock is priced for perfection and the implied move likely understates de-rating risk if guidance is cautious.
• If CW beats and raises but the stock gaps higher, fade strength into the close with a starter short position or put spread; target 5-10% downside over 2-6 weeks as valuation reverts toward peers.
• Pair trade: long a lower-multiple defense industrial with clearer backlog monetization versus short CW for 1-3 months; the spread should work if the market rotates from “best story” to “best value.”
• For longer-duration exposure, wait for a 7-10% pullback before initiating a long in CW; reward improves materially only if you can buy execution at a less stretched multiple.
• Watch for any commentary on backlog conversion speed and margin mix; if those indicators improve, consider adding via call spreads rather than stock to cap downside from valuation compression.